Mikhail Blagosklonny is one of the most distinguished academicians and scientists in the field of oncology and cancer research. His qualification includes M.D and Ph. D, and due to extensive achievements in the field of cancer research and associated fields, he was appointed as Professor of Oncology at one of the most reputed institutes in the world for cancer research, Roswell Park Cancer Institute, in April 2009.
Till date, Mikhail Blagosklonny has authored over 170 research articles, journal articles, book chapters and reviews. He is also the Editor and Editor in Chief of one of the most reputed medical journals namely Cell Cycle.
He is also associate editor of numerous other reputed journals in the field of medical science and research, which includes PLOS ONE, Cancer Biology, American Journal of Pathology, Cancer Biology and Therapy, Cell Death and Differentiation, Cancer Research, International Journal of Cancer, and Autophagy.
According to Nature, Mikhail Blagosklonny has worked rigorously and researched with great insight on various topics that include reducing ageing process and fighting cancer. After completing his M.D and PhD in cardiology and experimental treatment and medicine, from First Pavlov State Medical University of St. Petersburg, he joined as an associate professor at New York Medical College in 2002.
Later on, he joined Ordway Research Institute as a senior scientist. And, after working there for several years and making his mark considerably in the field of oncology, he finally joined Roswell Park Cancer Institute as a professor.
Most of his research is focused on cancer and focused cancer therapies to protect the cells from rapid damage, and also biogerontology, which deals in understanding the mechanism of ageing.
Impact Journals reports that after extensive research in the field, Mikhail Blagosklonny has proposed the use of the popular cancer drug named Rapamycin, which can help with controlling TOR Signalling.
According to his research, Rapamycin can help effectively in life extension. In the field of longevity research, he has made generous contributions and has been an active advocate for the use of Rapamycin.